CAR

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, November 2, 2023

“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.

Key Points: 
  • “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
  • Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
  • Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023

PHILADELPHIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, today announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, will be featured during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego.

Key Points: 
  • The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, will be featured during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego.
  • CNTY-101 is the Company’s first allogeneic cell therapy product candidate engineered with multiple complementary functionalities designed to enhance its product profile.
  • Pharmacokinetic measurements demonstrated that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation.
  • The Company believes these preliminary data support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits.

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

Retrieved on: 
Thursday, November 2, 2023

An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.

Key Points: 
  • An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.
  • This data supports robust neutrophil engraftment of trem-cel and provides evidence of hematologic protection from MylotargTM, a CD33-targeted antibody drug conjugate.
  • An updated data release from VBP101 is expected by the Relapse After Transplant and Cellular Therapy (HSCT²) conference taking place November 10-11, 2023.
  • Dr. Tasian commented: “The interim results from our CD33 CAR T cell immunotherapy clinical trial are very encouraging.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.

Key Points: 
  • The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
  • “We demonstrate that combination of the ΔPD1-IL12 with TGFBR2 KO not only enhanced CAR-T cell activity but surprisingly limit their accumulation outside the tumor, therefore reducing the risks of off-tumor toxicity.
  • These cells also show strong anti-tumor activity against distal tumors when infused intratumorally”, said Laurent Poirot, Ph.D., SVP Immunology at Cellectis.
  • These pre-clinical data highlight the capability of multi-armored allogeneic CAR T-cells to preserve their activity despite the immunosuppressive microenvironment, while mitigating potential safety concerns.

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

Retrieved on: 
Tuesday, October 31, 2023

ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.

Key Points: 
  • ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.
  • Presentation details were as follows:
    This presentation highlights updated survival data from the 21 subjects who were enrolled in two dose escalation groups in IRB-approved studies in China.
  • The median OS is approximately 24 months in dose level 2 with 4 of the 8 patients still alive.
  • The Company’s Phase 1 study of GCC19CART is enrolling patients with R/R mCRC at multiple sites in the U.S.

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

Retrieved on: 
Tuesday, October 31, 2023

“We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.”

Key Points: 
  • “We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.”
    Details on the presentations are below.
  • Lyell’s Epi-R manufacturing protocols are designed to generate populations of TIL with stem-like properties to potentially improve antitumor activity.
  • Epi-R P2 is an improved TIL manufacturing process that reduces the TIL culture duration to less than three weeks without impacting the quality of TIL.
  • These new nonclinical data show TIL rejuvenated with Lyell’s technology retain a broad TCR repertoire and demonstrate improved T-cell function and antitumor properties.

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

Retrieved on: 
Monday, October 30, 2023

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy.

Key Points: 
  • RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy.
  • This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.
  • KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those not effectively treatable with traditional methods.
  • Afterward, CAR T-cells are infused into the patient's arm, which is closely monitored for four weeks to ensure the body's adaptation.

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Monday, October 30, 2023

ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients. In addition to study enrollments completed at the City of Hope Medical Center (Duarte, California), the trial will be initiating enrollment of eligible patients at Wake Forest Baptist Medical Center (Winston Salem, North Carolina), the University of Massachusetts Medical Center (Worcester, Massachusetts), and Fred Hutchinson Cancer Research Center (Seattle, Washington).

Key Points: 
  • ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients.
  • Such patients often have difficulty mounting an adequate protective antibody response after receiving currently available COVID-19 vaccines.
  • In the U.S., there are approximately 15 million individuals who, as a result of their compromised immune systems, often do not adequately respond to the current authorized vaccines.
  • These data support the progression of the Phase 2 clinical study, which includes a direct comparison to currently approved mRNA vaccines.

Allogene Therapeutics Announces Participation in November Investor Conferences

Retrieved on: 
Monday, October 30, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in November.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in November.

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, November 6, 2023

Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • Cellares’ innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through its TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.
  • With automation, standardization, and software-defined manufacturing (SDM), subsequent tech transfers become instant to any other Cell Shuttle in any IDMO Smart Factory worldwide.